AMRX — Amneal Pharmaceuticals, Inc. Class A Common Stock · P/E 44, rev $1.52B

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.

Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.

Use this AMRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AMRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AMRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Amneal Pharmaceuticals, Inc. Class A Common Stock even when a live quote feed is slow.

Amneal Pharmaceuticals, Inc. Class A Common Stock latest statements (FY2025)

Latest cached year on this hub. Full AMRX income, balance, and cash tables.

  • Revenue$3.02B
  • Net Income$72.1M
  • Total Assets$3.68B
  • Total Debt$0
  • Free Cash Flow$269.9M

AMRX recent filings